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Recent breakthroughs in psychiatric genetics have implicated biological pathways onto which 
genetic risk for psychiatric disorders converges. However, these studies do not reveal the 
developmental time point(s) at which these pathways are relevant.  
Methods 
We aimed to determine the relationship between psychiatric risk and developmental gene 
expression relating to discrete biological pathways. We used post-mortem RNA sequencing 
data (BrainSeq and BrainSpan) from brain tissue at multiple prenatal and postnatal timepoints, 
with summary statistics from recent genome-wide association studies of schizophrenia, bipolar 
disorder and major depressive disorder. We prioritised gene sets for overall enrichment of 
association with each disorder, then tested the relationship between the association of their 
constituent genes with their relative expression at each developmental stage.  
Results 
We observed relationships between the expression of genes involved in voltage-gated cation 
channel activity during Early Midfetal, Adolescence and Early Adulthood timepoints and 
association with schizophrenia and bipolar disorder, such that genes more strongly associated 
with these disorders had relatively low expression during Early Midfetal development and higher 
expression during Adolescence and Early Adulthood. The relationship with schizophrenia was 
strongest for the subset of genes related to calcium channel activity, whilst for bipolar disorder 
the relationship was distributed between calcium and potassium channel activity genes.  
Conclusions 
Our results indicate periods during development when biological pathways related to the activity 
of calcium and potassium channels may be most vulnerable to the effects of genetic variants 
conferring risk to psychiatric disorders. Furthermore, they indicate key timepoints and potential 










Biological insight to psychiatric disorders has come from the identification of molecular 
pathways enriched for genetic association, determined by large cohort genome-wide studies. 
However, the expression of many genes varies as a function of age, and therefore the 
relevance of genetically associated pathways likely varies across development.  
Schizophrenia, bipolar disorder (BD) and major depressive disorder (MDD) show considerable 
heritability and share a substantial component of genetic risk (1–6). Variance between the 
disorders may in part be attributed to differences in the degree of neurodevelopmental 
impairment (3, 7, 8). Many psychiatric symptoms first present during adolescence or in early 
adulthood (9), implying that pathophysiology emerges as the brain matures (10). However, there 
is substantial evidence that altered neurodevelopment during earlier prenatal or postnatal 
periods may contribute to some, if not all, psychiatric disorders (3, 11–14). Identifying the 
developmental stage at which particular biological pathways are most likely to contribute to risk 
for psychiatric disorders is therefore an important step towards understanding disease etiology 
and targeting new treatments.  
Genetic association studies of schizophrenia have consistently demonstrated a convergence of 
genetic risk upon sets of genes with synaptic functions (15–19), including discrete signal 
transduction pathways such as voltage-gated calcium channel complexes and glutamate 
receptor complexes. The most recent genome-wide association studies (GWAS) of BD and 
MDD also highlight genes and pathways related to synaptic activity (20–23). Hence, signalling 
complexes in the synaptic membrane represent strong candidates for psychiatric drug targeting. 
Neurodevelopment is regulated by a program of tightly controlled gene expression (24, 25). The 
majority of GWAS loci linked to psychiatric disorders are non-coding and most likely mediate 
risk by affecting gene expression (26–29). Genes harbouring risk for schizophrenia and BD are 









cortical regions (30–32). However, the question of the developmental stage at which genes and 
gene pathways associated with major psychiatric diseases are primarily expressed remains 
largely unresolved, limiting our ability to reduce risk and target treatments. 
By integrating developmental transcriptomic data of the human brain with GWAS data of genetic 
risk in schizophrenia, BD and MDD, we aimed to identify time points at which gene sets 
implicated in risk for psychiatric disorder are most strongly expressed, in view of highlighting 
periods when key biological pathways may preferentially confer risk to these disorders.  
Methods and Materials 
Genotype data 
We obtained common variant summary statistics from published genome-wide association 
study (GWAS) data. The schizophrenia sample (40,675 cases, 64,643 controls) (17) is a meta-
analysis of a GWAS derived from UK cohorts of patients taking clozapine (11,260 cases, 24,542 
controls) and an international Psychiatric Genomics Consortium (PGC) study (29,415 cases, 
40,101 controls) (33). Case-control samples for BD were compiled by the PGC from 32 cohorts 
of European descent (20,352 cases, 31,358 controls) (21). Genotype data for MDD (135,458 
cases and 344,901 controls) were derived from a PGC meta-analysis of seven cohorts of 
European descent (22). For direct comparison of genetic factors contributing to schizophrenia 
and BD, we utilised additional summary statistics from a published GWAS of cases (23,585 
schizophrenia, 15,270 BD) matched for ancestry and genotyping platform (34). 
Transcriptomic data 
Human brain transcriptomic data from across the lifespan were obtained from two sources. A 









individuals with no history of psychiatric condition, referred to as BrainSeq (31). Samples ranged 
in age from second trimester to 85 years (Table S1). Tissue acquisition, processing and 
genotyping are described previously (31, 35). We obtained a second, smaller human 
developmental transcriptomic dataset from the Allen Institute BrainSpan Atlas (36, 37), from 
which we retained data for DLPFC samples (N = 40) ranging from the first trimester to 40 years 
(Table S1). 16 samples from BrainSeq and BrainSpan originated from the same individuals; 
these were removed from BrainSeq to ensure independence. Raw sequencing reads from 
Brainseq and BrainSpan were processed using the same software pipeline (38–41). Gene 
counts were converted to RPKM values (calculated in relation to the number of gene-assigned 
reads). 
Gene sets 
Gene sets defined by biological pathways were curated from the Gene Ontology (GO) database 
(42) (January 13th 2020), excluding gene annotations with evidence codes NAS (Non-traceable 
Author Statement), IEA (Inferred from Electronic Annotation) or RCA (inferred from Reviewed 
Computational Analysis). For primary analyses, gene sets containing fewer than 100 genes 
were excluded to minimize the effect of outliers. After filtering, 1766 gene sets remained (Table 
S2A). 
Further gene ontology definitions were obtained from the SynGO database (43), consisting of 
manually-curated gene annotations of synaptic function and location. After filtering for sets 
containing at least 100 genes, 19 sets remained (Table S4A). 
Gene set association analysis 
Gene set association analysis was performed in MAGMA v1.08b (44). Using GWAS summary 
statistics, SNPs with a minor allele frequency greater than 1% were annotated to genes, 









association statistics were calculated using the SNP-wise mean model with the 1000 Genomes 
European reference panel (46) to control for linkage disequilibrium. Gene set association was 
calculated using a background of all genes, conditional on the brain expression of each gene. 
Brain expression was defined as log2(RPKM + 0.5), where RPKM is the mean average across 
BrainSeq samples.  
Primary analyses aimed to identify gene sets significantly enriched for GWAS association 
signal. Stepwise conditional analyses were applied to significantly (FDR < 0.05) (47) associated 
gene sets to identify a reduced number of independent sets that efficiently summarise the 
biological themes underlying the association. During this process, gene sets were repeatedly 
retested for genetic association, each time selecting the set with the highest effect size and 
adding that set to the conditional variables. On each iteration, gene sets that were no longer 
nominally significant (unadjusted P ≥ 0.05) were excluded. This procedure results in gene sets 
that may have small amounts of overlap but contribute substantially distinct genetic risk. 
In secondary analyses, we tested the relative association of subsets compared to a larger set by 
adding the larger set to the model as a conditional variable. Comparisons of genetic association 
between non-overlapping gene sets were performed using a z-test of beta values. 
Developmental gene expression scores 
Transcriptomic data were divided into developmental stages (Table S1). Stages containing 
fewer than two samples in BrainSpan or BrainSeq were excluded for that dataset. Accordingly, 
two samples from BrainSeq were excluded (one Early Fetal, one Late Infancy). Late Adulthood 
was not represented in BrainSpan. To permit comparison between genes and control for 
covariates, we constructed a score measuring the expression of each gene at each 








fitting a linear regression model to each gene using limma (48) and extracting the t-statistic for 
each developmental stage term:  
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Developmental stage is a binary variable indicating whether the sample is from that stage or 
not. We controlled for genetic ancestry by covarying for the first five principal components 
defining sample genotypes (snpPC).  
Expression-association relationships 
For selected gene sets, we assessed the relationship between developmental stage gene 
expression and association with a disorder using MAGMA (v1.08b) interaction analysis (49): 
 =  +  + ! + !"" + !"" + # 
In this model, the interaction term !" is defined as the product of gene set membership ! and 
gene property !" terms. This method determined whether enrichment for genetic association in 
a gene set is stronger for genes with a higher expression score. Due to sensitivity to outlier 
effects in smaller sets, primary analyses were restricted to sets ≥ 100 genes (49). Interaction 
analyses were two-tailed and statistical correction was performed for each gene set at each 
developmental stage using the Bonferroni method (P.adj). Analyses yielding significant 
interactions in one disorder were repeated as secondary analyses in the remaining disorders.  
Clustering of developmental expression trajectories 
To generalise expression analyses specific to each developmental stage to the complete 
expression trajectory across all stages, we partitioned gene sets of interest into subsets of 
genes with similar trajectories. Gene expression at each stage (mean RPKM) was scaled by 









K-means clustering was identified using a scree plot. The procedure was run using 20 sets of 
random partitions, allowing for a maximum of 20 iterations. Gene set association analyses were 
used to test for enrichment of GWAS signal in gene clusters. 
Results 
Independently associated gene ontologies 
To select gene sets for downstream analyses, we performed gene set association analysis on a 
filtered list of 1766 GO-derived gene sets. Following FDR correction, we observed 57 gene sets 
enriched for association with schizophrenia (Table S2A) and 11 associated with BD (Table 
S2B). No sets remained significantly associated with MDD (Table S2C). Due to redundancy 
between GO terms, we used conditional analyses to select gene sets with independent 
associations. This procedure yielded 6 sets independently associated with schizophrenia (Table 
S2A) and 2 sets independently associated with BD (Table S2B). Genes related to voltage-gated 
cation channel activity (VG-cation) were enriched for association with schizophrenia (β = 0.43, 
FDR = 6.2×10-04) and BD (β = 0.32, FDR = 0.025), but not MDD (β = 0.14, FDR = 1.0). Of 125 
genes in the VG-cation set, only one gene, CACNA1C, surpassed gene-wide significance (P < 
2.5×10-06) (50) for association with both schizophrenia and BD (Figure S1A). Using a more 
exploratory threshold of gene-wide association (P < 1×10-04), we noted three further genes 
contributing risk to both disorders (Figure S1B-D).  
Developmental stage-specific relationships between gene 
expression and genetic association within biological pathways 
We used BrainSeq transcriptomic data to determine whether enrichment for common variant 









preferentially expressed during particular developmental stages. In analyses of genes annotated 
by VG-cation, we observed a significant positive interaction term for the relationship between 
expression during Early Adulthood and genetic association with both schizophrenia (β = 0.15, 
P.adj = 0.0090; Table S3A) and BD (β = 0.15, P.adj = 0.0022; Table S3B) (Figure 1A,B). This 
indicates that, during Early Adulthood, VG-cation genes more strongly associated with 
schizophrenia or BD have relatively high DLPFC expression compared to other developmental 
stages, whilst those lacking association have relatively low expression (Figure S2). Conversely, 
during Early Midfetal development (10-15 post-conceptual weeks), there was a negative 
relationship (indicating that genes more associated with the disorder have relatively low DLPFC 
expression and less associated genes have higher expression) between VG-cation expression 
and association with BD (β = -0.047, P.adj = 0.011). 
For comparison, we tested these temporal relationships with VG-cation expression in MDD 
genetic risk. VG-cation expression was not related to association with MDD at any 
developmental stage (Figure 1C).  
We repeated analyses of developmental VG-cation expression using an independent 
transcriptomic dataset, BrainSpan. Overall, the pattern of preferential VG-cation expression 
across development was consistent between BrainSeq and BrainSpan (Figure 1D-F), such that 
early embryonic expression exhibited the strongest negative relationship with association with 
schizophrenia (Early Fetal: β = -0.16, P = 0.0035; Early Midfetal: β = -0.053, P = 0.30) and BD 
(Early Fetal: β = -0.084, P = 0.086; Early Midfetal: β = -0.10, P = 0.024) and positive 
relationships were observed during Early Adulthood (schizophrenia: β = 0.32, P = 0.0017; BD: β 
= 0.26, P = 0.0071). BrainSpan VG-cation gene expression during Adolescence was also 
strongly positively related to association with schizophrenia (β = 0.32, P = 8.7×10-05) and BD (β 
= 0.21, P = 0.0038). Again, no relationships were observed between VG-cation temporal 









Multiple synaptic pathways, including those related to voltage-gated ion channels, have been 
previously implicated in risk for psychiatric disorders (15). To assess the specificity of our 
findings, we studied an independent dataset of synaptic gene annotations for generalisation. 
Using manually-curated gene sets from the SynGO database (43), we repeated gene set 
association and developmental interaction analyses. From these sets, independent genetic 
associations were found for 3 gene sets with schizophrenia and 3 with BD (Tables S4A-B). 
None of these SynGO gene sets exhibited developmental patterns of expression that were 
linked to genetic association (Tables S5A-B).  
Partitioning association between child terms of voltage-gated 
cation channel activity 
The VG-cation term (125 genes) is composed of four nested “child” GO terms: voltage-gated 
potassium channel activity (VG-potassium, 80 genes), voltage-gated calcium channel activity 
(VG-calcium; 38 genes), NMDA glutamate receptor activity (7 genes) and voltage-gated proton 
channel activity (1 gene). To examine whether genetic association of VG-cation with 
schizophrenia and BD is further enriched in the smaller and more biologically specific “child” 
terms (excluding voltage-gated proton channel activity due to size), we performed gene set 
analysis of these terms conditional on VG-cation. VG-calcium showed greater enrichment for 
association with schizophrenia than the full VG-cation set (Table 1). Conversely, association 
with BD was not further enriched within the “child” terms (Table 1), indicating even distribution 
across subtypes of VG-cation.  
Based on the differing contributions of VG-cation “child” terms to genetic association with 
schizophrenia and BD, we hypothesised that VG-calcium and VG-potassium are points of 
genetic divergence between the two disorders. We repeated the above gene set analyses using 
summary statistics from a schizophrenia vs BD GWAS (34). We found differential enrichment for 








manifested significantly in VG-potassium (β = 0.21, P = 0.015) but not VG-calcium (β = 0.15, P 
= 0.16) (Table 1). 
We examined the contribution of VG-calcium and VG-potassium to the developmental patterns 
of preferential risk gene expression in VG-cation. Developmental relationships during Early 
Midfetal and Early Adulthood stages between gene expression and schizophrenia association 
were more prominent in VG-calcium than VG-potassium genes (Early Midfetal: z-test P = 0.039; 
Early Adulthood: z-test P = 0.020) (Figure 2A). Conversely, these relationships in analyses of 
BD appeared more pronounced among VG-potassium genes (Figure 2B), although 
comparisons of effect sizes showed no significant differences at these stages (Early Midfetal: z-
test P = 0.49; Early Adulthood: z-test P = 0.20), likely due to the larger set size of VG-potassium 
compared to VG-calcium giving greater significance for a given effect size. These analyses also 
strengthened the evidence that positive expression-association relationships begin in 
Adolescence and continue into Early Adulthood.  
Together, these results suggest that the VG-cation subset involved in calcium activity are further 
enriched for association with schizophrenia, with those more strongly associated being 
preferentially expressed during Adolescence and Early Adulthood. In contrast, calcium and 
potassium subsets exhibit a more balanced association with BD, and a greater dominance of 
preferential risk gene expression during Early Adulthood among potassium activity genes. 
Partitioning association by developmental expression trajectory 
Our developmental stage-specific analyses suggest that VG-cation genes with low Early 
Midfetal and high Adolescence / Early Adulthood expression are enriched for association with 
schizophrenia and BD. They also suggest that the schizophrenia association is stronger for the 
VG-calcium subset. To generalise these hypotheses across all developmental stages we 
identified subsets of genes with similar expression trajectories and tested the distribution of 









cation genes (Figure 3; Figure S3; Table S6). Association with schizophrenia and BD was 
restricted to Clusters 1 and 2, both of which contain genes with lower embryonic expression and 
higher expression in later life (Figure 3). Only Cluster 2 (containing genes exhibiting later peak 
expression than Cluster 1) harbored greater enrichment for association with schizophrenia and 
BD than VG-cation genes as a whole (schizophrenia: P.conditional = 3.6×10-05; BD: 
P.conditional = 0.010).  
On splitting these clusters into VG-calcium and VG-potassium, we observed that association of 
Clusters 1 and 2 with schizophrenia was stronger among VG-calcium genes than VG-potassium 
genes (Cluster 1: z-test P = 0.0019; Cluster 2: z-test P = 6.4×10-04) and only the VG-calcium 
subsets showed greater enrichment for association than VG-cation as a whole (VG-calcium 
Cluster 1: P.conditional = 0.0062; VG-calcium Cluster 2: P.conditional = 2.6×10-06; VG-
potassium Cluster 1: P.conditional = 0.99; VG-potassium Cluster 2: P.conditional = 0.36). 
Association of the same clusters with BD was distributed between VG-calcium and VG-
potassium subsets (Cluster 1: z-test P = 0.98; Cluster 2: z-test P = 0.75), which were not more 
enriched than the full VG-cation gene set (VG-calcium Cluster 1: P.conditional = 0.42; VG-
calcium Cluster 2: P.conditional = 0.11; VG-potassium Cluster 1: P.conditional = 0.39; VG-
potassium Cluster 2: P.conditional = 0.081).  
Discussion 
Our study highlights biological convergence among common variants conferring risk to 
schizophrenia and BD in genes annotated by the ontological term voltage-gated cation channel 
activity (VG-cation) and identifies adolescence and early adulthood as periods of preferential 
expression for the most strongly associated members in both disorders. In schizophrenia, these 
temporal relationships derived predominantly from the calcium-related component of VG-cation, 
voltage-gated calcium channel activity (VG-calcium), whilst in BD they were driven by both VG-









we observed no relationship between genetic association with MDD and preferential VG-cation 
gene expression at any developmental stage.  
Enrichment for genetic association with schizophrenia, BD and MDD in genes encoding voltage-
gated calcium channel subunits has been consistently reported in primary GWAS (17, 21, 22), 
with additional genetic evidence supporting their involvement in schizophrenia from rare variants 
(19, 51). Whilst molecular abnormalities in calcium activity have historically been regarded as 
specific to BD (52–54), recent work suggests that alterations in cellular calcium may be 
comparable between schizophrenia and BD (55, 56). The voltage-gated calcium channel family 
are signal transducers of electrical excitation in neurons. Through the induction of intracellular 
calcium transients, they couple membrane depolarization to signalling cascades including 
activity-dependent regulation of gene expression (57). In this way, voltage-gated calcium 
channels influence synaptic plasticity and are thought to be important drivers of learning and 
memory (58).  
Unlike schizophrenia, genetic association with BD in VG-cation was distributed between calcium 
and potassium components. Whilst it is typically unfeasible to compare across disorders due to 
differences in statistical power, we used summary statistics from a recent schizophrenia vs BD 
GWAS (34) to demonstrate that VG-potassium genes are differentially enriched for association 
with schizophrenia and BD. Voltage-gated potassium channels have been linked to BD through 
genetic studies previously (21, 59–63), and this represents a divergence from schizophrenia 
and MDD which lack evidence of conferring risk through potassium channels. Notably, the GO 
term, response to potassium ion, was the only pathway reported to be significantly differentially 
enriched for association in gene set analyses from the primary schizophrenia vs BD GWAS 
(34). The broad function of voltage-gated potassium channels is to control the threshold for 
action potentials and repolarise the membrane after firing (64). Like calcium channels, they 









Our results suggest that Adolescence and Early Adulthood are periods of peak preferential 
DLPFC expression of VG-cation genes associated with schizophrenia and BD. This lends to the 
idea that these developmental stages, which correspond to peak periods of symptom onset, 
may be more vulnerable to risk conferred through cation channels. Conversely, Early Midfetal 
development was characterised by comparably low expression of risk VG-cation genes, 
perhaps indicating a period of low vulnerability in this pathway. These conclusions are drawn 
from the assumption that peak expression relates to periods of high functional activity and the 
greatest impact of genetic variants. We cannot rule out, however, that change in the function of 
a gene expressed in relatively low abundance could mediate substantial risk.  
More specifically, these periods of preferential gene expression in schizophrenia-associated 
VG-cation genes were characterised by more prominent relationships within the VG-calcium 
subset. Conversely, preferential expression of BD-associated VG-cation genes was agnostic to 
the cation subset. This discrepancy raises the possibility that VG-calcium genes, but not VG-
potassium genes, contribute to an Adolescence / Early Adulthood vulnerability to schizophrenia, 
whilst both subsets contribute to BD vulnerability during the same period. 
Due to research bias and varying evidence quality, the database of GO annotations is 
undoubtedly incomplete. For example, the VG-cation GO term examined here does not include 
subsets related to sodium channel activity. Voltage-gated sodium channels have been linked to 
schizophrenia and autism in sequencing studies (51, 67, 68) and are involved in the 
pharmacodynamics of mood stabilizers used in the treatment of BD (69). Secondly, VG-calcium 
includes a small number of stargazin-like proteins, initially linked to voltage-gated calcium 
channels via homology, but with functions related to membrane expression of AMPA receptors, 
and are now collectively known as transmembrane AMPA receptor regulatory proteins (TARPs) 
(70). 
Due to its manual curation, the SynGO database of synaptic annotations (43) is likely to have 









they include multiple gene sets annotated to synaptic pathways consistently implicated in 
psychiatric disorders (15–19). Whilst some SynGO terms were enriched for association with 
schizophrenia or BD, the risk conferred was not related to periods of preferential gene 
expression. These results provide evidence that the developmental profile of schizophrenia and 
BD risk associated with GO VG-cation genes does not generalise to other synaptic pathways. 
Our results reflect trends in gene sets, but expression patterns of individual genes or transcripts 
associated with psychiatric disorder may vary. For example, CACNA1C (encoding calcium 
channel CaV1.2) contains a locus with genome-wide evidence for association with 
schizophrenia, BD and MDD (17, 21, 71–73) and is the single-gene cause of Timothy 
syndrome, a disorder of multiorgan maldevelopment (74). CACNA1C is reported to reach peak 
brain expression in late fetal / early childhood development (75, 76) and its forebrain deletion in 
embryonic, but not adult, mice models endophenotypes of psychiatric disorders (77). However, 
around 250 splice variants of CACNA1C have been reported (78), with varying expression 
profiles. Further, it is still unclear which of the CACNA1C transcripts is associated with risk 
variants identified from GWAS. To better understand developmental vulnerability to genetic risk 
conferred through cation channels, the expression patterns of transcripts relevant to psychiatric 
disorders should be characterised independently of the gene-wide expression.  
Our study employed transcriptomic data derived from the DLPFC, a region long thought to be 
impacted in schizophrenia and mood disorders (79–81). Compared to other brain regions, the 
DLPFC is considered to be late-maturing (82, 83) and exhibits some distinct developmental 
gene expression trajectories (84, 85). Hence, the relationships between genetic risk and 
developmental expression in other brain regions might be different or create age-specific 
vulnerabilities in other biological pathways that could account for the emergence of different 
psychiatric symptoms. 
There is strong evidence that early developmental stages contribute to psychiatric 








Using similar methodology, our previous work (30) demonstrated that among all brain-
expressed genes there is a bias for those with stronger genetic association to be preferentially 
expressed in the prefrontal cortex during early midfetal development (schizophrenia) or early 
infancy (schizophrenia / BD). Other biological pathways associated with psychiatric disorders 
may be most vulnerable to genetic risk during prenatal or early postnatal life, but were not 
identified by the current study. 
Our findings have implications for the targeting of therapeutics. Psychiatric disorders are 
insufficiently treated, yet voltage-gated cation channels have been recognised as potential 
targets for new (or existing) compounds (66, 86) and their druggability is an area of active 
research (87, 88). Preferential expression of genetically associated genes during ages typical of 
diagnosis reinforces the suitability of voltage-gated cation channels as targets. Our results also 
indicate periods when therapeutic agents acting on such pathways may be most effective.  
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Figure 1 Developmental stage-specific relationships between the expression of voltage gated 
cation channel activity genes and genetic association with psychiatric disorders. Shown is -
log10(P)×sgn(z) from independent MAGMA interaction analyses of common variant association 
and gene expression scores derived from BrainSeq or BrainSpan at each developmental stage, 
compared to a background of all genes. Dotted lines indicate thresholds for statistical 
significance after correcting for analyses of all gene sets with independent association with the 
disorder, and all stages (Tables S3A,B). MDD analyses were corrected for the number of stages 
only. Developmental stages containing fewer than 2 samples in the dataset are not represented. 
Early Fetal, 8-9 postconceptual weeks (pcw); Early Midfetal, 10-15 pcw; Midfetal, 16 pcw; Late 
Midfetal, 17-23 pcw; Late Fetal, 24-37 pcw; Early Infancy, 0-5 months; Late Infancy, 6-11 
months; Early Childhood, 1-5 years; Late Childhood, 6-12 years; Adolescence, 13-19 years; 
Early Adulthood, 20-29 years; Mid Adulthood, 30-59 years; Late Adulthood, 60-100 years. 
 
Figure 2 Comparison of expression-association relationships at 11 developmental stages within 
voltage-gated cation channel activity “child” terms. Shown is -log10(P)×sgn(z) from MAGMA 
interaction analyses of schizophrenia or BD common variant association and BrainSeq-derived 
gene expression scores at each stage, compared to a background of all genes. Dotted lines 
indicate thresholds for statistical significance after correcting for analyses of two gene sets 
across 11 stages. GO:0022843 Voltage-gated cation channel activity, N = 125; GO:0005245 
Voltage-gated calcium channel activity, N = 38; GO:0005249 Voltage-gated potassium channel 
activity, N = 80. 
 
Figure 3 Clusters of developmental expression trajectories of voltage-gated cation channel 
activity genes and their enrichments for GWAS association in schizophrenia and BD. K-means 
clustering was used to divide genes based on their mean RPKM expression in BrainSeq across 
11 developmental stages. Tabulated are results from schizophrenia and BD gene set 
association analyses of each expression trajectory cluster, with separation into voltage-gated 









Gene set N 
Schizophrenia Bipolar disorder Schizophrenia vs 
bipolar disorder 












80 0.12 0.15 1.0 0.25 0.0080 0.87 0.21 0.015 
NMDA glutamate 
receptor activity 
7 0.90 0.014 0.12 0.61 0.046 0.20 0.12 0.35 
 
Table 1 The relative genetic association of voltage-gated cation channel activity “child” terms 
compared to the complete gene set in two psychiatric disorders. Shown is the output from gene 
set association analysis in MAGMA before (P) and after (P.cond) conditioning on the full 
voltage-gated cation channel activity gene set. Also shown are results from contrasting the 
genetic contributions to the two disorders by gene set association analyses with summary 































Gene set Cluster N 
Schizophrenia Bipolar disorder 
β P β P 
Voltage-gated cation 
channel activity 
1 27 0.39 0.019 0.36 0.023 
2 55 0.85 6.9×10-10 0.52 1.4×10-05 
3 17 -0.09 0.62 0.39 0.084 
4 25 -0.14 0.75 -0.26 0.92 
Voltage-gated calcium 
channel activity 
1 9 1.19 8.4×10-05 0.38 0.14 
2 16 1.59 3.0×10-9 0.58 0.0085 
3 3 0.48 0.20 0.51 0.19 
4 10 -0.09 0.61 0.081 0.40 
Voltage-gated potassium 
channel activity 
1 17 -0.04 0.57 0.37 0.045 
2 36 0.49 0.0021 0.49 6.2×10-04 
3 11 -0.54 0.92 0.35 0.17 
4 15 -0.23 0.81 -0.54 0.99 
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